Latest Insights on IMMU
Profit From AbbVie’s Struggles TodayAbbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.
Investors’ Survival Guide to the CoronavirusThe coronavirus is spreading fear through global markets. But there is one beaten-down sector that will emerge from the global crisis even stronger. Anthony Planas reveals the No. 1 fund that every investor should add to their portfolio today.
3D Printing + Precision Medicine = Massive 2020 ProfitsPrecision medicine just took a massive leap forward. This mega medical trend in personalized health care offers investors huge profit potential.
2 Biotech Stocks to Grab Before Their 2020 BreakoutBiotech stocks are naturally speculative. You don’t want to use your lunch money to buy them. But they can deliver life-changing gains.
Sometimes, It’s Lupus; Sage’s Depressing Results
December 5, 2019 Great StuffThe Right Prescription for Massive Returns Today, dear readers, we’re going to cover a topic I just know you all love and adore: biotechnology. I can hear the groans already … and I get it. All those big scary words that have no real meaning to you at all. It’s like they’re talking about some […]